Lantern Pharma LTRN 深 滬
等待開盤 07-18 09:30:00 美东时间
4.28
+0.290
+7.27%
華盛通- 最 高4.43
- 今 開3.99
- 成交量 15.15万股
- 最 低 3.962
- 昨 收 3.99
- 總市值 4615.85万
- 52周最高 6.118
- 市盈率 靜 --
- 換手率 1.40%
- 52周最低 2.55
- 委 比 60.44%
- 總股本 1078.47万
- 歷史最高 24.84
- 量 比 0.74
- 振 幅 11.73%
- 歷史最低 2.38
- 每 手 1
- 風險率 1.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lantern Pharma Secures FDA Approval For Phase 1B/2 Clinical Trial For LP-184 + Olaparib In Triple-Negative Breast Cancer
The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair
07-15 21:42
Lantern Pharma Enters $15.53M At-The-Market Offering Agreement With ThinkEquity
On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the "Sales Agreement") with ThinkEquity LLC (the "Agent"), pursuant to which the Company may offer and
07-04 04:14
Lantern Pharma Announces Preclinical Data For LP-184 In Atypical Teratoid Rhabdoid Tumors, Rare And Aggressive Pediatric Brain Cancer
Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trialLantern Pharma Inc.
05-29 20:32
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Vigil Neuroscience (NASDAQ:VIGL) stock increased by 243.7% to $7.94 du...
05-22 20:10
Lantern Pharma Advances AI-Driven Cancer Therapies
Lantern Pharma, Inc. ( ($LTRN) ) has released its Q1 earnings. Here is a breakd...
05-16 11:57
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
Lantern Pharma's Earnings Outlook
Lantern Pharma (NASDAQ:LTRN) will release its quarterly earnings report on Thur...
05-15 05:02
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.
05-12 20:31
Lantern Pharma Q4 2024 GAAP EPS $(0.54) Misses $(0.51) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 38.46 percent decrease over losses of $(0.39) per share from
03-28 04:28
